← Back to Search

Amino Acid

Glutamine for Indigestion

Phase 1 & 2
Recruiting
Led By David Cangemi, MD
Research Sponsored by David J. Cangemi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks

Summary

This trial is studying the effects of glutamine on patients with functional dyspepsia, a condition causing stomach discomfort. Glutamine is a protein building block that provides energy to gut cells and helps keep the gut lining strong. Researchers want to see if glutamine can improve symptoms and compare its safety and effectiveness. Glutamine has been studied for its potential benefits in reducing neurotoxicity in patients receiving chemotherapy, showing some degree of benefit in reducing symptoms like paresthesias and constipation.

Who is the study for?
This trial is for people in good health with functional dyspepsia, which causes indigestion. They must fit the Rome IV criteria for this condition and can't have allergies to certain sugars, liver or kidney problems, be pregnant or breastfeeding, use tobacco heavily, drink excessively, or have had recent stomach surgery.
What is being tested?
Researchers are testing if glutamine—an amino acid that fuels intestinal cells—can improve symptoms of functional dyspepsia compared to a placebo. The study will measure safety and effectiveness by observing changes in intestinal permeability.
What are the potential side effects?
While not explicitly listed here, potential side effects may include digestive discomfort since glutamine affects gut function. However, as an amino acid naturally present in the body, it's generally considered safe at recommended doses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Change in Functional Dyspepsia symptoms
Change in symptoms of bloating
+1 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Glutamine GroupActive Control1 Intervention
Subjects will receive glutamine for 28 days.
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects will receive placebo for 28 days.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Glutamine, an essential amino acid, is a key treatment for indigestion as it provides energy to gastrointestinal cells and strengthens the intestinal wall, preventing harmful substances from exacerbating symptoms. This is crucial for maintaining a healthy gut barrier. Other common treatments include antacids, H2-receptor antagonists, and proton pump inhibitors, which alleviate indigestion by neutralizing or reducing stomach acid production.
Arteriovenous differences for amino acids across control and acid-secreting rat stomach in vivo.Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle.[Duodenogastric reflux in patients with irritable bowel syndrome treated with wheat bran].

Find a Location

Who is running the clinical trial?

David J. CangemiLead Sponsor
David Cangemi, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials

Media Library

Glutamine (Amino Acid) Clinical Trial Eligibility Overview. Trial Name: NCT05655819 — Phase 1 & 2
Indigestion Clinical Trial 2023: Glutamine Highlights & Side Effects. Trial Name: NCT05655819 — Phase 1 & 2
Glutamine (Amino Acid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05655819 — Phase 1 & 2
~0 spots leftby Dec 2024